Mohammed G. Ghonime

Aswan University — Egypt

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index626citations39works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(22), CAR-T cell therapy research(21), Herpesvirus Infections and Treatments(6), Inflammasome and immune disorders(5), Cytomegalovirus and herpesvirus research(4)

Publications39 total

Enterococcus faecium and Clostridium butyricum combined with selenium as alternatives to the antibiotic colistin: impacts on growth, cecal fermentation, and immune function in rabbits raised under hot environmental conditions
Frontiers in Animal Science·2025· 2 citedOpen Access
Intermittent light program impacts on reproductive performance, health and welfare of breeding hens
Archives animal breeding/Archiv für Tierzucht·2023· 3 citedOpen Access
274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Abstract ND02: CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors
Cancer Research·2023· 13 cited
Supplementary Figure 1 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Figure Legends from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Figure 4 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Table 1 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Figure 4 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Data from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Figure 2 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Data from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Figure 2 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Figure Legends from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Figure 3 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Table 1 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Figure 1 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Figure 3 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Figure 5 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
Supplementary Figure 5 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Kevin A. Cassady(25), Ramadan A. El-Domany(6), Mikhail A. Gavrilin(6), Mark D. Wewers(5), O.R. Shamaa(4), Srabani Das(3), Justin C. Roth(3), Elaine R. Mardis(3), Jonathan Terrett(3), Demetrios Kalaitzidis(3), Robert Chain(3), Zinkal Padalia(3), Meghna Kuppuraju(3), Brigid McEwan(3), James M. Markert(2), Ahmed Abdelaziz(2), Hesham S. M. Soliman(2), Joel Lee(2), Ruoning Wang(2), Mary‐Lee Dequéant(2)